The Lancet publishes results of the PHERGain clinical trial on breast cancer

Barcelona, April 4 (EFE) - The medical specialty journal The Lancet has published the results of the PHERGain clinical trial, conducted by MEDSIR, showing that one-third of patients with localized HER2-positive breast cancer could be cured without the need for chemotherapy.

Metadata

Date: 04/04/2024 11:08 (UTC)
Credit: EFE
Source: EFE
Topic: Science and technology
Type: Ready-to-use w/ voice over
Duration: 121 seconds
Reference: 7001351243
Relevance: Normal

Product Suggestions

Stories

Reportajes general América

Video

EFE VÍDEO

Photo

Gráfico general América

Photo

Gráfico general y gráfico territorial EUA-Caribe.

Text

EFE International News

Multimedia

Contenidos digitales general multimedia América

Photo

EFE Photo

Text

EFE News Latino